More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/(S)-Roscovitine [186692-45-5]
Chemical Structure
Chemical Structure
Chemical Structure

(S)-Roscovitine [186692-45-5]

Research Use Only
AG-MR-C0002
AdipoGen Life Sciences
CAS Number186692-45-5
DownloadMSDS
Product group Chemicals
Estimated Purity>99%
Molecular Weight354.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    (S)-Roscovitine [186692-45-5]
  • Delivery Days Customer
    10
  • CAS Number
    186692-45-5
  • Certification
    Research Use Only
  • Estimated Purity
    >99%
  • Molecular Formula
    C19H26N6O
  • Molecular Weight
    354.5
  • Scientific Description
    (S)-enantiomer of (R)-roscovitine (Prod. No. MR-C0001). Potent selective cyclin-dependent kinase 1 (CDK1) inhibitor. Potential neuroprotectant for stroke. Crosses the blood brain barrier. Inhibits CDK5, consequently blocking hypoxia-induced apoptosis in neurons. Potential anti-inflammatory compound. Potential antidiabetic compound. - Chemical. CAS: 186692-45-5. Formula: C19H26N6O. MW: 354.5. (S)-enantiomer of (R)-roscovitine (Prod. No. MR-C0001). Potent selective cyclin-dependent kinase 1 (CDK1) inhibitor. Potential neuroprotectant for stroke. Crosses the blood brain barrier. Inhibits CDK5, consequently blocking hypoxia-induced apoptosis in neurons. Potential anti-inflammatory compound. Potential antidiabetic compound.
  • SMILES
    CC[C@@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    51202000

References

  • Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5: L. Meijer, et al.; Eur. J. Biochem. 243, 527 (1997)
  • Maintenance of meiotic arrest in bovine oocytes using the S-enantiomer of roscovitine: effects on maturation, fertilization and subsequent embryo development in vitro: P. Coy, et al.; Reprod. 129, 19 (2005)
  • Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models: B. Menn, et al.; PLoS One 5, e12117 (2010)